Gene · 868
Papers1,946
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,946
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discovery of Phosphorylated Peptidomimetics Targeting Cbl-b SH2 Domain as Orthosteric Cbl-b Inhibitors by an Optimized Fluorescence Polarization Competition Assay. | J Med Chem | 2025 | 40851258 | PubTator, text mining | PubMed |
| Combination of Cbl-b inhibitor NX-1607 and CDK4/6 inhibitor abemaciclib enhances anti-tumor immunity through PLCγ1/ERK-mediated T cell activation. | Cell Signal | 2025 | 40774352 | PubTator, text mining | PubMed |
| RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications. | MedComm (2020) | 2025 | 40761481 | PubTator, text mining | PubMed |
| Exosome circ-CBLB promotes M1 macrophage polarization in rheumatoid arthritis through the TLR3/TRAF3 signaling axis. | Front Immunol | 2025 | 40746530 | PubTator, text mining | PubMed |
| A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia. | Blood Cancer J | 2025 | 40745181 | PubTator, text mining | PubMed |
| WTAP modulates macrophage polarization in rheumatoid arthritis by targeting exosomal circ-CBLB via m6A modification. | Front Immunol | 2025 | 40557140 | PubTator, text mining | PubMed |
| Mesenchymal stem cell-derived exosomal CBLB ameliorates infantile pneumonia progression probably by ubiquitinating MAPK14. | J Inflamm (Lond) | 2025 | 40537786 | PubTator, text mining | PubMed |
| Bridging chemical space and biological efficacy: advances and challenges in applying generative models in structural modification of natural products. | Nat Prod Bioprospect | 2025 | 40478370 | PubTator, text mining | PubMed |
| Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment. | Research (Wash D C) | 2025 | 40463500 | PubTator, text mining | PubMed |
| Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation. | J Immunother Cancer | 2025 | 40447319 | PubTator, text mining | PubMed |
| circ-0001454 alleviates asthma airway inflammation and remodeling via sponging miR-770-5p and regulating cbl-b. | Front Cell Dev Biol | 2025 | 40264707 | PubTator, text mining | PubMed |
| CBLB Regulates MAPK-P38 Pathway via MAP3K9 Ubiquitination to Inhibit GBM Cell Invasion and Migration. | J Cell Physiol | 2025 | 40254893 | PubTator, text mining | PubMed |
| Single-Cell Transcriptome and RNA Sequencing Reveal Immune-Related Markers of Preeclampsia. | Reprod Sci | 2025 | 40216654 | PubTator, text mining | PubMed |
| Integrating genomic features for prognosis in Chinese patients with B-cell lymphoma following chimeric antigen receptor T-cell therapy. | Sci China Life Sci | 2025 | 40189492 | PubTator, text mining | PubMed |
| Alternative splicing analysis in a Spanish ASD (Autism Spectrum Disorders) cohort: in silico prediction and characterization. | Sci Rep | 2025 | 40155475 | PubTator, text mining | PubMed |
| Ubiquitin Ligases in Control: Regulating NLRP3 Inflammasome Activation. | Front Biosci (Landmark Ed) | 2025 | 40152367 | PubTator, text mining | PubMed |
| Revisiting the role of CBL in liver fibrosis: Unveiling the antifibrotic potential of CBLB inhibitor NX-1607. | J Hepatol | 2025 | 40139509 | PubTator, text mining | PubMed |
| Possible Trace of HTLV-1 Virus in Modulation of Cbl-b, ITCH, and PP2A Suppressor Genes. | Int J Mol Cell Med | 2025 | 40123588 | PubTator, text mining | PubMed |
| Rational design, optimization, and biological evaluation of novel pyrrolo-pyridone derivatives as potent and orally active Cbl-b inhibitors. | Eur J Med Chem | 2025 | 40120499 | PubTator, text mining | PubMed |
| Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs. | Cell | 2025 | 40101708 | Swiss-Prot, curated | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/868/papers?page=3